SABRTooth: a randomised controlled feasibility study of stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I nonsmall cell lung cancer considered to be at higher risk of complications from surgical resection

Kevin N. Franks, Lucy McParland, Joanne Webster, David R. Baldwin, David Sebag-Montefiore, Matthew Evison, Richard Booton, Corinne Faivre-Finn, Babu Naidu, Jonathan Ferguson, Clive Peedell, Matthew E.J. Callister, Martyn Kennedy, Jenny Hewison, Janine Bestall, Walter M. Gregory, Peter Hall, Fiona Collinson, Catherine Olivier, Rachel Naylor, Sue Bell, Peter Allen, Andrew Sloss, Michael Snee

Source: Eur Respir J, 56 (5) 2000118; 10.1183/13993003.00118-2020

Journal Issue: November

Disease area: Thoracic oncology

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Kevin N. Franks, Lucy McParland, Joanne Webster, David R. Baldwin, David Sebag-Montefiore, Matthew Evison, Richard Booton, Corinne Faivre-Finn, Babu Naidu, Jonathan Ferguson, Clive Peedell, Matthew E.J. Callister, Martyn Kennedy, Jenny Hewison, Janine Bestall, Walter M. Gregory, Peter Hall, Fiona Collinson, Catherine Olivier, Rachel Naylor, Sue Bell, Peter Allen, Andrew Sloss, Michael Snee. SABRTooth: a randomised controlled feasibility study of stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I nonsmall cell lung cancer considered to be at higher risk of complications from surgical resection. Eur Respir J, 56 (5) 2000118; 10.1183/13993003.00118-2020

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Clinical outcomes of stereotactic ablative body radiotherapy (SABR) in medically inoperable early stage lung cancer patients Source: Virtual Congress 2021 – Therapy of lung cancer Year: 2021
Factors predicting complete surgical resection after induction chemotherapy in patients with initially unresectable non-small cell lung cancer (NSCLC) treated in a randomised trial Source: Eur Respir J 2003; 22: Suppl. 45, 162s Year: 2003
Long-term follow-up comparing postoperative chemotherapy or radiotherapy and surgery with surgery alone in resectable nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 131s Year: 2001
Impact of neoadjuvant therapies on surgical indications and early postoperative outcome Source: Annual Congress 2005 - Multidisciplinary treatment of non-metastatic non-small cell lung cancer: contemporary concepts Year: 2005
Surgical treatment of lung cancer after polyhemothetapy/radiotherapy down-staging in patients initially assessed as inoperable Source: Eur Respir J 2006; 28: Suppl. 50, 718s Year: 2006
ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy) Source: Eur Respir J 2009; 34: 17-41 Year: 2009
Locally advanced disease – indications and results of extended resections Source: Annual Congress 2005 - Borderline indications for surgical treatment of non-small cell lung cancer Year: 2005
Respective indications of chemotherapy, radiotherapy and surgery in limited disease stage small cell lung carcinoma Source: Annual Congress 2005 - Neuroendocrine tumours of the lung Year: 2005
Long time survival after resection for multiple primary lung cancers. A population-based study Source: Annual Congress 2005 - New insights into prognosis in thoracic surgical oncology Year: 2005
Early complications after lung resections at patients treated for lung cancer with and without neoadjuvant hemiotheraphy Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011
Survival and postoperative complication after neoadjuvant therapy in resectable stage IIIA-N2 non-small cell lung cancer: a balancing exercise Source: Eur Respir J 2003; 22: Suppl. 45, 31s Year: 2003
Combined and organ-saving operations in patients with advanced lung cancer after induction chemotherapy Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010
Pre-operative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage nonsmall cell lung cancer Source: Breathe 2010; 7: 196-197 Year: 2010
Outcome after pneumonectomy in non small cell lung cancer patients receiving a neoadjuvant therapy Source: Eur Respir J 2004; 24: Suppl. 48, 478s Year: 2004
Improved overall survival after early recurrence of lung cancer following the introduction of CT-based follow-up for patients initially treated with curative intent by (chemo)radiotherapy (CRT). Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up Year: 2017
A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 162s Year: 2003
ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy) Source: Guideline 2009 Year: 2009
Surgical and survival outcomes of sleeve lobectomy after neoadjuvant theraphy in lung cancer: With group of 265 patients Source: Virtual Congress 2021 – COVID-19 and management of lung cancer Year: 2021
Salvage lung resection for local recurrence after stereotactic body radiotherapy for primary and metastatic lung cancers Source: Annual Congress 2011 - General thoracic surgery I Year: 2011